The National Institute for Health and Care Excellence

New AI tools could help spot prostate cancer more accurately

Innovative AI technologies have the potential to act like a ‘second pair of eyes’, helping radiologists review prostate MRI scans.
National Institute for Health and Care Excellence

News, blogs and podcasts

Around 1,000 people with HER2-low advanced breast cancer can now be offered Enhertu after NICE recommended it for routine NHS use. People with obsessive-compulsive disorder (OCD) and body dysmorphic ...
National Institute for Health and Care Excellence

Prostate cancer

All NICE products on prostate cancer. Includes any guidance, advice and quality standards.
National Institute for Health and Care Excellence

Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer (terminated evaluation)

NICE is unable to make a recommendation on lurbinectedin (Zepzelca) with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer in adults. This is because the company ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Reducing the risk of transmission of Creutzfeldt–Jakob disease (CJD) from surgical instruments used for interventional procedures on high-risk tissues

We have moved interventional procedures guidance 666 to become HealthTech guidance 535. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment ...
National Institute for Health and Care Excellence

Sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)

NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not ...
National Institute for Health and Care Excellence

Crohn’s disease: management

This guideline covers managing Crohn’s disease in children, young people and adults. It aims to reduce people’s symptoms and maintain or improve their quality of life. NICE has also produced a ...
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Dabrafenib plus trametinib for treating BRAF V600 mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults. There is a commercial access agreement ...
National Institute for Health and Care Excellence

Secukinumab for treating moderate to severe plaque psoriasis in children and young people

Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years. Next review: This guidance will be reviewed if there ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.